MedTrace Logo

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

NCT04525885 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2024-01-12

Study results available
· View outcomes & findings →

Summary

The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

Conditions

  • Chronic Cough

Interventions

DRUG

Gefapixant 45 mg twice daily (BID)

Gefapixant 45 mg tablet to be administered orally BID

DRUG

Gefapixant 15 mg BID

Gefapixant 15 mg tablet to be administered orally BID

DRUG

Placebo

Placebo tablet administered orally BID

DRUG

Gefapixant 45 mg BID

Gefapixant 45 mg tablet to be administered orally BID

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-17
Primary Completion
2022-09-15
Completion
2022-09-15
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04525885 on ClinicalTrials.gov